 |
|
Patients with history of cancer at increased risk for acquiring and dying from sepsis
June 14, 2006ATLANTA- Hospitalized patients with a history of cancer are at a ten-fold increased risk of acquiring and subsequently dying from sepsis— a severe immune response to an infection—compared to hospitalized patients without cancer, according to research by investigators at the Emory University School of Medicine. In addition, the risk for sepsis among male patients was found to be 30 percent greater than for female patients, while African Americans and other races had nearly twice the risk for sepsis of Caucasian patients. The results are reported in the June issue of Chest, the peer-reviewed journal of the American College of Chest Physicians (ACCP).
The study utilized data from 1979 to 2001 from the National Hospital Discharge Survey (NHDS) and the Surveillance, Epidemiology, and End Results (SEER) databases. Conducted by Emory physicians Greg Martin, MD, MSc, Marc Moss, MD, and Pajman Danai, MD from the Division of Pulmonary, Allergy and Critical Care, and by David Mannino, MD, of the University of Kentucky, Division of Pulmonary and Critical Care Medicine, the research is the first to present nationally representative longitudinal data for the impact of sepsis among cancer patients and to examine gender and racial disparities in this condition.
The NHDS database from the years 1979 to 2001 included 854 million hospitalizations, of which 76.7 million involved a co-existing diagnosis of malignancy, and nearly 11 million involved sepsis. Sepsis occurred in 2.3 percent of all the cancer patients, or 1.7 million patients. According to the study, during the 23-year study period, the number of sepsis cases in patients with cancer increased from 24,150 in 1979 to 87,160 in 2001, representing an increase of 261 percent during the study period. Of the sepsis patients with a history of cancer, gastrointestinal malignancies were most common at 24.4 percent, followed by lung (20 percent), lymphoma (14.1 percent), prostate (9.3 percent), and breast cancers (8.8 percent). Patients with pancreatic cancer were found to have the highest incidence of sepsis, even greater than for leukemia.
Sepsis occurs when the intended protective and reparative immune response becomes exaggerated and causes problems throughout the body, such as acute renal failure and lung failure. Previous Emory studies have concluded that sepsis is an increasingly common and life-threatening condition across the United States, having risen to the tenth leading cause of death overall in this country, and that it afflicts persons of all ages.
In the study, Emory investigators conclude that cancer is a strong independent predictor of mortality from sepsis due to compromised immune systems. The use of chemotherapy, radiation, or other immune modulating therapy employed to combat the underlying malignancy are some of the reasons for patients' increased susceptibility to sepsis.
Dr. Martin says that although sepsis can occur in anyone, there are certain factors that make sepsis more likely.
"People of older age are more likely to develop sepsis, and certain co-morbid medical conditions, such as HIV, are known to increase the risk of sepsis because of their influence on normal immune function," he said. "There is very little data on how sepsis affects cancer patients, although physicians generally feel that cancer patients are more susceptible to sepsis because the normal immune system is altered, either because of the cancer itself or because of chemotherapy. Based on the data in this paper, we now know that cancer is clearly one of those conditions that increases the risk for sepsis—in this case by 10 times."
Dr. Martin also says that other findings from the research are important for physicians who take care of either cancer patients or sepsis patients. Care of sepsis patients requires antibiotics, usually prescribed based upon the suspected source of infection. For cancer patients, the source of sepsis is highly related to the type of cancer. Lung cancer patients, for instance, are more likely to get respiratory infections as a cause of sepsis, while patients with prostate cancer are more likely to develop urinary infections and patients with gastro-intestinal malignancies are more likely to develop abdominal sepsis.
"This is potentially useful for physicians in both preventing infections that may cause sepsis, and in treating cancer patients who present with sepsis," Dr. Martin explained.
The case-fatality rate for sepsis was highest in the study for patients with lung cancer, at 40 percent, compared to approximately 26 percent for patients with other types of cancer, such as breast, prostate and skin cancer.
The study also reveals that sepsis incidence rates are higher among cancer patients than among patients with other conditions commonly considered to increase the risk of sepsis. Out of 100,000 cancer patients in the U.S., for example 1,075 developed sepsis, compared to 1,051 per 100,000 patients with HIV/AIDS or 701 per 100,000 patients with diabetes. Sepsis patients with cancer overall had a 55 percent greater risk of dying than sepsis patients without cancer, and after adjusting for other factors that may influence the risk of dying (such as the type of infection or severity of illness), sepsis patients with cancer were twice as likely to die compared to sepsis patients without cancer.
"There is a striking increase in the risk of dying with sepsis that appears to be directly attributable to the diagnosis of cancer," Dr. Martin says.
Emory University Health Sciences Center
Sepsis occurs when the intended protective and reparative immune response becomes exaggerated and causes problems throughout the body, such as acute renal failure and lung failure. Previous Emory studies have concluded that sepsis is an increasingly common and life-threatening condition across the United States, having risen to the tenth leading cause of death overall in this country, and that it afflicts persons of all ages.
In the study, Emory investigators conclude that cancer is a strong independent predictor of mortality from sepsis due to compromised immune systems. The use of chemotherapy, radiation, or other immune modulating therapy employed to combat the underlying malignancy are some of the reasons for patients' increased susceptibility to sepsis.
Dr. Martin says that although sepsis can occur in anyone, there are certain factors that make sepsis more likely.
"People of older age are more likely to develop sepsis, and certain co-morbid medical conditions, such as HIV, are known to increase the risk of sepsis because of their influence on normal immune function," he said. "There is very little data on how sepsis affects cancer patients, although physicians generally feel that cancer patients are more susceptible to sepsis because the normal immune system is altered, either because of the cancer itself or because of chemotherapy. Based on the data in this paper, we now know that cancer is clearly one of those conditions that increases the risk for sepsis—in this case by 10 times."
Dr. Martin also says that other findings from the research are important for physicians who take care of either cancer patients or sepsis patients. Care of sepsis patients requires antibiotics, usually prescribed based upon the suspected source of infection. For cancer patients, the source of sepsis is highly related to the type of cancer. Lung cancer patients, for instance, are more likely to get respiratory infections as a cause of sepsis, while patients with prostate cancer are more likely to develop urinary infections and patients with gastro-intestinal malignancies are more likely to develop abdominal sepsis.
"This is potentially useful for physicians in both preventing infections that may cause sepsis, and in treating cancer patients who present with sepsis," Dr. Martin explained.
The case-fatality rate for sepsis was highest in the study for patients with lung cancer, at 40 percent, compared to approximately 26 percent for patients with other types of cancer, such as breast, prostate and skin cancer.
The study also reveals that sepsis incidence rates are higher among cancer patients than among patients with other conditions commonly considered to increase the risk of sepsis. Out of 100,000 cancer patients in the U.S., for example 1,075 developed sepsis, compared to 1,051 per 100,000 patients with HIV/AIDS or 701 per 100,000 patients with diabetes. Sepsis patients with cancer overall had a 55 percent greater risk of dying than sepsis patients without cancer, and after adjusting for other factors that may influence the risk of dying (such as the type of infection or severity of illness), sepsis patients with cancer were twice as likely to die compared to sepsis patients without cancer.
"There is a striking increase in the risk of dying with sepsis that appears to be directly attributable to the diagnosis of cancer," Dr. Martin says.
Emory University Health Sciences Center
Sepsis Current Events and Sepsis News RSSA Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.
Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.
Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.
OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.
Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
 |
Sepsis: New Strategies for Management by Jordi Rello (Editor), Marcos I. Restrepo (Editor) Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of Sepsis: New Strategies is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract. |
 |
Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine) by Edward Abraham (Editor), Mervyn Singer (Editor) There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis. |
 |
Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor) Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies. |
 |
Deep Sea Creatures by Monstrum Sepsis Monstrum Sepsis (Performer) Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms. |
 |
Primordial Notions Delta 2001-2004 Monstrum Sepsis (Primary Contributor) |
|
Bacteria Sepsis: Video 1 of 3 [VHS] Starring: Diane Charsha | |
 |
Management of Sepsis: the PIRO Approach by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor) Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe... |
 |
Sepsis (Competency-Based Critical Care) by Simon V. Baudouin (Editor) Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The... |
 |
Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs) by Novartis IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such... |
 |
Primordial Notions Gamma 1996-2000 Monstrum Sepsis (Primary Contributor) |
| © 2009 BrightSurf.com |